References National Cancer Institute. (2020, October 26). Radiopharmaceuticals: radiation therapy enters the molecular age....

Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Zabrina Watkins Radical welcomeness “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do this,...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

March 7, 2025 – rivaroxaban 2.5 mg tablet (Xarelto) Lupin launched a generic to Janssen’s Xarelto Factor Xa inhibitor indicated (1) to reduce the risk of major cardiovascular events in patients...

Tennessee In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were executed on...

Event features Prime's Health Outcomes team

Forbes

Commercial formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series Prescription Drug Guide NetResults™ Balanced Drug Guide NetResults™ F-Series...

New or expanded indications March 12, 2025 – fluocinolone acetonide intravitreal implant (Iluvien) Alimera; corticosteroid; supplemental NDA (sNDA) approved for consolidation of labeling of...

This form is specifically used to request a check reissue. For remittance requests, please use the following link: Pharmacy remittance request - Prime Therapeutics LLC. Prime Therapeutics cannot...

Disclaimer THIS WEBSITE IS AN OPTIONAL RESOURCE FOR HEALTH CARE PROVIDERS ONLY. IF YOU ARE NOT A HEALTH CARE PROVIDER OR AUTHORIZED PROFESSIONAL USER, YOU ARE NOT TO USE THIS SITE AT ALL AND ARE...

Category Migration Site ID Liferay Token Category Type Old Categories New Read Category Prime Article Type Dry Run - preview only, do not update content Migration UpdateType Migration Output Log

New approach aligns with long-standing biosimilar strategy

December 2024 December 2023 December 2021 Pharmacy newsletter from Prime Therapeutics that provides information and updates about Prime services. June 2022 Home Other Navigation Pharmacy +...

publications Fall 2024 Prime Therapeutics Report October 21, 2024 Debuting a new name and design, the 41st edition of our managed care report still offers the same in-depth industry articles on...

publications Summer 2024 Prime Therapeutics Report June 11, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. This issue’s cover story...

July 17, 2026 publications 2026 Medical Pharmacy Trend Report: Part 2 – Drug Overview The 2026 Medical Pharmacy Trend Report: Part 2 – Drug Overview reflects Prime Therapeutics’ long‑standing...

cover image for 2026 Medical Pharmacy Trend Report: Part 1 - Payer Survey Packed with insights on real-world management trends for the hottest industry topics Prime Therapeutics...